期刊
CANCER BIOLOGY & THERAPY
卷 13, 期 13, 页码 1319-1324出版社
LANDES BIOSCIENCE
DOI: 10.4161/cbt.21792
关键词
USP9X; p53; chemotherapy; 5-fluorouracil; apoptosis; resistance; gene targeting
类别
资金
- Johns Hopkins SPORE in gastrointestinal cancer [P50CA062924]
- National Cancer Institute [R01157535, T32CA121937]
The X-linked deubiquitinase USP9X affects the stability and activity of numerous regulatory proteins that influence cell survival. Recent studies suggest that decreased USP9X expression can confer a selective advantage onto developing cancer cells and thereby promotes disease progression. To examine the effect of USP9X on the cellular responses to anticancer therapies, we derived cancer cell lines in which the USP9X locus was disrupted by homologous recombination. The resulting USP9X-deficient cancer cells exhibited increased activation of apoptotic pathways and markedly decreased clonogenic survival in response to 5-fluorouracil, a chemotherapeutic drug that is widely used for treatment of gastrointestinal malignancies. These unexpected results suggest that cancers with low USP9X expression might be specifically sensitized to some conventional therapeutic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据